nodes	percent_of_prediction	percent_of_DWPC	metapath
Efavirenz—Cytochrome P450 3A4 Inhibitors—Cyclosporine—psoriasis	0.582	1	CiPCiCtD
Efavirenz—CYP1A2—Clobetasol propionate—psoriasis	0.0389	0.143	CbGbCtD
Efavirenz—CYP2B6—Cholecalciferol—psoriasis	0.0231	0.0848	CbGbCtD
Efavirenz—CYP1A2—Methoxsalen—psoriasis	0.0204	0.075	CbGbCtD
Efavirenz—CYP2D6—Hydroxyurea—psoriasis	0.0184	0.0676	CbGbCtD
Efavirenz—CYP2C19—Cholecalciferol—psoriasis	0.0147	0.0539	CbGbCtD
Efavirenz—CYP3A4—Calcitriol—psoriasis	0.0138	0.0505	CbGbCtD
Efavirenz—CYP2C9—Cholecalciferol—psoriasis	0.0122	0.0448	CbGbCtD
Efavirenz—CYP2D6—Cholecalciferol—psoriasis	0.0111	0.041	CbGbCtD
Efavirenz—CYP3A4—Methoxsalen—psoriasis	0.0107	0.0393	CbGbCtD
Efavirenz—CYP2C19—Prednisone—psoriasis	0.0102	0.0373	CbGbCtD
Efavirenz—CYP2B6—Dexamethasone—psoriasis	0.00998	0.0367	CbGbCtD
Efavirenz—CYP2C19—Cyclosporine—psoriasis	0.00963	0.0354	CbGbCtD
Efavirenz—CYP2C9—Cyclosporine—psoriasis	0.00801	0.0294	CbGbCtD
Efavirenz—CYP2D6—Cyclosporine—psoriasis	0.00732	0.0269	CbGbCtD
Efavirenz—CYP3A4—Cholecalciferol—psoriasis	0.00708	0.026	CbGbCtD
Efavirenz—CYP2C19—Dexamethasone—psoriasis	0.00634	0.0233	CbGbCtD
Efavirenz—CYP3A4—Mycophenolate mofetil—psoriasis	0.00614	0.0226	CbGbCtD
Efavirenz—CYP3A4—Triamcinolone—psoriasis	0.00614	0.0226	CbGbCtD
Efavirenz—CYP2C9—Dexamethasone—psoriasis	0.00527	0.0194	CbGbCtD
Efavirenz—CYP3A4—Betamethasone—psoriasis	0.00527	0.0194	CbGbCtD
Efavirenz—CYP3A4—Prednisolone—psoriasis	0.0052	0.0191	CbGbCtD
Efavirenz—CYP3A4—Hydrocortisone—psoriasis	0.00493	0.0181	CbGbCtD
Efavirenz—CYP3A4—Prednisone—psoriasis	0.00491	0.018	CbGbCtD
Efavirenz—CYP2D6—Dexamethasone—psoriasis	0.00482	0.0177	CbGbCtD
Efavirenz—CYP3A4—Cyclosporine—psoriasis	0.00466	0.0171	CbGbCtD
Efavirenz—CYP3A4—Dexamethasone—psoriasis	0.00307	0.0113	CbGbCtD
Efavirenz—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.000742	0.0826	CbGpPWpGaD
Efavirenz—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000561	0.0624	CbGpPWpGaD
Efavirenz—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000516	0.0574	CbGpPWpGaD
Efavirenz—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000511	0.0569	CbGpPWpGaD
Efavirenz—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000481	0.0535	CbGpPWpGaD
Efavirenz—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00046	0.0512	CbGpPWpGaD
Efavirenz—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000347	0.0387	CbGpPWpGaD
Efavirenz—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00032	0.0356	CbGpPWpGaD
Efavirenz—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000317	0.0353	CbGpPWpGaD
Efavirenz—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000271	0.0301	CbGpPWpGaD
Efavirenz—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000209	0.0233	CbGpPWpGaD
Efavirenz—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000191	0.0213	CbGpPWpGaD
Efavirenz—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000188	0.021	CbGpPWpGaD
Efavirenz—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000155	0.0172	CbGpPWpGaD
Efavirenz—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000144	0.0161	CbGpPWpGaD
Efavirenz—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000142	0.0158	CbGpPWpGaD
Efavirenz—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000133	0.0148	CbGpPWpGaD
Efavirenz—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000132	0.0146	CbGpPWpGaD
Efavirenz—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000131	0.0146	CbGpPWpGaD
Efavirenz—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00013	0.0144	CbGpPWpGaD
Efavirenz—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000117	0.013	CbGpPWpGaD
Efavirenz—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000112	0.0125	CbGpPWpGaD
Efavirenz—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000111	0.0123	CbGpPWpGaD
Efavirenz—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000108	0.012	CbGpPWpGaD
Efavirenz—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000107	0.0119	CbGpPWpGaD
Efavirenz—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.11e-05	0.0101	CbGpPWpGaD
Efavirenz—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.77e-05	0.00976	CbGpPWpGaD
Efavirenz—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.68e-05	0.00966	CbGpPWpGaD
Efavirenz—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.56e-05	0.00953	CbGpPWpGaD
Efavirenz—CYP2B6—Biological oxidations—CYP2S1—psoriasis	8.22e-05	0.00915	CbGpPWpGaD
Efavirenz—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	8.11e-05	0.00903	CbGpPWpGaD
Efavirenz—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.03e-05	0.00783	CbGpPWpGaD
Efavirenz—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	6.94e-05	0.00772	CbGpPWpGaD
Efavirenz—CYP2C19—Biological oxidations—CYP2S1—psoriasis	6.21e-05	0.00691	CbGpPWpGaD
Efavirenz—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	6.13e-05	0.00682	CbGpPWpGaD
Efavirenz—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.11e-05	0.0068	CbGpPWpGaD
Efavirenz—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.04e-05	0.00673	CbGpPWpGaD
Efavirenz—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	6.02e-05	0.0067	CbGpPWpGaD
Efavirenz—CYP2D6—Biological oxidations—CYP2S1—psoriasis	5.71e-05	0.00636	CbGpPWpGaD
Efavirenz—CYP2C9—Biological oxidations—CYP2S1—psoriasis	5.67e-05	0.00631	CbGpPWpGaD
Efavirenz—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	5.64e-05	0.00627	CbGpPWpGaD
Efavirenz—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	5.59e-05	0.00622	CbGpPWpGaD
Efavirenz—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	5.54e-05	0.00617	CbGpPWpGaD
Efavirenz—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	5.51e-05	0.00613	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	5.39e-05	0.006	CbGpPWpGaD
Efavirenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.16e-05	0.00575	CbGpPWpGaD
Efavirenz—CYP1A2—Biological oxidations—CYP2S1—psoriasis	4.84e-05	0.00539	CbGpPWpGaD
Efavirenz—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	4.77e-05	0.00531	CbGpPWpGaD
Efavirenz—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	4.77e-05	0.0053	CbGpPWpGaD
Efavirenz—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	4.69e-05	0.00522	CbGpPWpGaD
Efavirenz—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.21e-05	0.00469	CbGpPWpGaD
Efavirenz—CYP1A2—Tryptophan metabolism—CAT—psoriasis	4.18e-05	0.00465	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.99e-05	0.00444	CbGpPWpGaD
Efavirenz—CYP3A4—Biological oxidations—CYP2S1—psoriasis	3.74e-05	0.00416	CbGpPWpGaD
Efavirenz—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.69e-05	0.0041	CbGpPWpGaD
Efavirenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.6e-05	0.00401	CbGpPWpGaD
Efavirenz—Feeling abnormal—Mycophenolate mofetil—psoriasis	3.59e-05	0.000262	CcSEcCtD
Efavirenz—Insomnia—Hydrocortisone—psoriasis	3.59e-05	0.000262	CcSEcCtD
Efavirenz—Hypertension—Betamethasone—psoriasis	3.59e-05	0.000262	CcSEcCtD
Efavirenz—Hypertension—Dexamethasone—psoriasis	3.59e-05	0.000262	CcSEcCtD
Efavirenz—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	3.58e-05	0.00399	CbGpPWpGaD
Efavirenz—Paraesthesia—Hydrocortisone—psoriasis	3.56e-05	0.00026	CcSEcCtD
Efavirenz—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.56e-05	0.00026	CcSEcCtD
Efavirenz—Urticaria—Cyclosporine—psoriasis	3.55e-05	0.000259	CcSEcCtD
Efavirenz—Myalgia—Dexamethasone—psoriasis	3.54e-05	0.000258	CcSEcCtD
Efavirenz—Myalgia—Betamethasone—psoriasis	3.54e-05	0.000258	CcSEcCtD
Efavirenz—Body temperature increased—Cyclosporine—psoriasis	3.53e-05	0.000258	CcSEcCtD
Efavirenz—Abdominal pain—Cyclosporine—psoriasis	3.53e-05	0.000258	CcSEcCtD
Efavirenz—Anxiety—Dexamethasone—psoriasis	3.52e-05	0.000257	CcSEcCtD
Efavirenz—Anxiety—Betamethasone—psoriasis	3.52e-05	0.000257	CcSEcCtD
Efavirenz—Vomiting—Mycophenolic acid—psoriasis	3.51e-05	0.000256	CcSEcCtD
Efavirenz—Discomfort—Betamethasone—psoriasis	3.49e-05	0.000255	CcSEcCtD
Efavirenz—Discomfort—Dexamethasone—psoriasis	3.49e-05	0.000255	CcSEcCtD
Efavirenz—Dyspepsia—Hydrocortisone—psoriasis	3.49e-05	0.000255	CcSEcCtD
Efavirenz—Rash—Mycophenolic acid—psoriasis	3.48e-05	0.000254	CcSEcCtD
Efavirenz—Dermatitis—Mycophenolic acid—psoriasis	3.48e-05	0.000254	CcSEcCtD
Efavirenz—Pain—Prednisolone—psoriasis	3.47e-05	0.000254	CcSEcCtD
Efavirenz—Hepatitis—Methotrexate—psoriasis	3.47e-05	0.000254	CcSEcCtD
Efavirenz—Urticaria—Mycophenolate mofetil—psoriasis	3.46e-05	0.000253	CcSEcCtD
Efavirenz—Headache—Mycophenolic acid—psoriasis	3.46e-05	0.000252	CcSEcCtD
Efavirenz—Decreased appetite—Hydrocortisone—psoriasis	3.45e-05	0.000252	CcSEcCtD
Efavirenz—Body temperature increased—Mycophenolate mofetil—psoriasis	3.44e-05	0.000251	CcSEcCtD
Efavirenz—Abdominal pain—Mycophenolate mofetil—psoriasis	3.44e-05	0.000251	CcSEcCtD
Efavirenz—Urinary tract disorder—Methotrexate—psoriasis	3.43e-05	0.00025	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.43e-05	0.00025	CcSEcCtD
Efavirenz—Fatigue—Hydrocortisone—psoriasis	3.42e-05	0.00025	CcSEcCtD
Efavirenz—Vision blurred—Prednisone—psoriasis	3.41e-05	0.000249	CcSEcCtD
Efavirenz—Urethral disorder—Methotrexate—psoriasis	3.4e-05	0.000249	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.4e-05	0.000249	CcSEcCtD
Efavirenz—Pain—Hydrocortisone—psoriasis	3.39e-05	0.000248	CcSEcCtD
Efavirenz—Insomnia—Triamcinolone—psoriasis	3.38e-05	0.000247	CcSEcCtD
Efavirenz—Ill-defined disorder—Prednisone—psoriasis	3.36e-05	0.000245	CcSEcCtD
Efavirenz—Paraesthesia—Triamcinolone—psoriasis	3.35e-05	0.000245	CcSEcCtD
Efavirenz—Feeling abnormal—Prednisolone—psoriasis	3.35e-05	0.000244	CcSEcCtD
Efavirenz—Visual impairment—Methotrexate—psoriasis	3.35e-05	0.000244	CcSEcCtD
Efavirenz—Anaemia—Prednisone—psoriasis	3.34e-05	0.000244	CcSEcCtD
Efavirenz—Shock—Betamethasone—psoriasis	3.34e-05	0.000244	CcSEcCtD
Efavirenz—Shock—Dexamethasone—psoriasis	3.34e-05	0.000244	CcSEcCtD
Efavirenz—Dyspnoea—Triamcinolone—psoriasis	3.33e-05	0.000243	CcSEcCtD
Efavirenz—Nervous system disorder—Betamethasone—psoriasis	3.32e-05	0.000243	CcSEcCtD
Efavirenz—Nervous system disorder—Dexamethasone—psoriasis	3.32e-05	0.000243	CcSEcCtD
Efavirenz—Agitation—Prednisone—psoriasis	3.32e-05	0.000243	CcSEcCtD
Efavirenz—Thrombocytopenia—Betamethasone—psoriasis	3.32e-05	0.000242	CcSEcCtD
Efavirenz—Thrombocytopenia—Dexamethasone—psoriasis	3.32e-05	0.000242	CcSEcCtD
Efavirenz—Tachycardia—Betamethasone—psoriasis	3.31e-05	0.000242	CcSEcCtD
Efavirenz—Tachycardia—Dexamethasone—psoriasis	3.31e-05	0.000242	CcSEcCtD
Efavirenz—Angioedema—Prednisone—psoriasis	3.31e-05	0.000241	CcSEcCtD
Efavirenz—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.3e-05	0.00367	CbGpPWpGaD
Efavirenz—Hypersensitivity—Cyclosporine—psoriasis	3.29e-05	0.00024	CcSEcCtD
Efavirenz—Dyspepsia—Triamcinolone—psoriasis	3.29e-05	0.00024	CcSEcCtD
Efavirenz—Erythema multiforme—Methotrexate—psoriasis	3.28e-05	0.00024	CcSEcCtD
Efavirenz—Nausea—Mycophenolic acid—psoriasis	3.28e-05	0.000239	CcSEcCtD
Efavirenz—Hyperhidrosis—Dexamethasone—psoriasis	3.28e-05	0.000239	CcSEcCtD
Efavirenz—Hyperhidrosis—Betamethasone—psoriasis	3.28e-05	0.000239	CcSEcCtD
Efavirenz—Feeling abnormal—Hydrocortisone—psoriasis	3.27e-05	0.000239	CcSEcCtD
Efavirenz—Malaise—Prednisone—psoriasis	3.26e-05	0.000238	CcSEcCtD
Efavirenz—Vertigo—Prednisone—psoriasis	3.25e-05	0.000237	CcSEcCtD
Efavirenz—Eye disorder—Methotrexate—psoriasis	3.25e-05	0.000237	CcSEcCtD
Efavirenz—Gastrointestinal pain—Hydrocortisone—psoriasis	3.24e-05	0.000237	CcSEcCtD
Efavirenz—Syncope—Prednisone—psoriasis	3.24e-05	0.000237	CcSEcCtD
Efavirenz—Tinnitus—Methotrexate—psoriasis	3.24e-05	0.000236	CcSEcCtD
Efavirenz—Anorexia—Betamethasone—psoriasis	3.23e-05	0.000236	CcSEcCtD
Efavirenz—Anorexia—Dexamethasone—psoriasis	3.23e-05	0.000236	CcSEcCtD
Efavirenz—Urticaria—Prednisolone—psoriasis	3.23e-05	0.000236	CcSEcCtD
Efavirenz—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.22e-05	0.00359	CbGpPWpGaD
Efavirenz—Cardiac disorder—Methotrexate—psoriasis	3.22e-05	0.000235	CcSEcCtD
Efavirenz—Fatigue—Triamcinolone—psoriasis	3.22e-05	0.000235	CcSEcCtD
Efavirenz—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.21e-05	0.000234	CcSEcCtD
Efavirenz—Asthenia—Cyclosporine—psoriasis	3.2e-05	0.000234	CcSEcCtD
Efavirenz—Pain—Triamcinolone—psoriasis	3.19e-05	0.000233	CcSEcCtD
Efavirenz—Loss of consciousness—Prednisone—psoriasis	3.18e-05	0.000232	CcSEcCtD
Efavirenz—Pruritus—Cyclosporine—psoriasis	3.16e-05	0.000231	CcSEcCtD
Efavirenz—Urticaria—Hydrocortisone—psoriasis	3.15e-05	0.00023	CcSEcCtD
Efavirenz—Angiopathy—Methotrexate—psoriasis	3.15e-05	0.00023	CcSEcCtD
Efavirenz—Immune system disorder—Methotrexate—psoriasis	3.14e-05	0.000229	CcSEcCtD
Efavirenz—Abdominal pain—Hydrocortisone—psoriasis	3.14e-05	0.000229	CcSEcCtD
Efavirenz—Body temperature increased—Hydrocortisone—psoriasis	3.14e-05	0.000229	CcSEcCtD
Efavirenz—Convulsion—Prednisone—psoriasis	3.13e-05	0.000229	CcSEcCtD
Efavirenz—Mediastinal disorder—Methotrexate—psoriasis	3.13e-05	0.000229	CcSEcCtD
Efavirenz—Asthenia—Mycophenolate mofetil—psoriasis	3.12e-05	0.000228	CcSEcCtD
Efavirenz—Hypertension—Prednisone—psoriasis	3.12e-05	0.000228	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.09e-05	0.000226	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Betamethasone—psoriasis	3.09e-05	0.000226	CcSEcCtD
Efavirenz—Pruritus—Mycophenolate mofetil—psoriasis	3.08e-05	0.000225	CcSEcCtD
Efavirenz—Arthralgia—Prednisone—psoriasis	3.08e-05	0.000225	CcSEcCtD
Efavirenz—Myalgia—Prednisone—psoriasis	3.08e-05	0.000225	CcSEcCtD
Efavirenz—Feeling abnormal—Triamcinolone—psoriasis	3.08e-05	0.000225	CcSEcCtD
Efavirenz—Anxiety—Prednisone—psoriasis	3.07e-05	0.000224	CcSEcCtD
Efavirenz—Alopecia—Methotrexate—psoriasis	3.07e-05	0.000224	CcSEcCtD
Efavirenz—Insomnia—Betamethasone—psoriasis	3.07e-05	0.000224	CcSEcCtD
Efavirenz—Insomnia—Dexamethasone—psoriasis	3.07e-05	0.000224	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.06e-05	0.000223	CcSEcCtD
Efavirenz—Diarrhoea—Cyclosporine—psoriasis	3.05e-05	0.000223	CcSEcCtD
Efavirenz—Paraesthesia—Betamethasone—psoriasis	3.04e-05	0.000222	CcSEcCtD
Efavirenz—Paraesthesia—Dexamethasone—psoriasis	3.04e-05	0.000222	CcSEcCtD
Efavirenz—Discomfort—Prednisone—psoriasis	3.04e-05	0.000222	CcSEcCtD
Efavirenz—Erythema—Methotrexate—psoriasis	3.02e-05	0.000221	CcSEcCtD
Efavirenz—Malnutrition—Methotrexate—psoriasis	3.02e-05	0.000221	CcSEcCtD
Efavirenz—Hypersensitivity—Prednisolone—psoriasis	2.99e-05	0.000219	CcSEcCtD
Efavirenz—Dyspepsia—Betamethasone—psoriasis	2.98e-05	0.000218	CcSEcCtD
Efavirenz—Dyspepsia—Dexamethasone—psoriasis	2.98e-05	0.000218	CcSEcCtD
Efavirenz—Diarrhoea—Mycophenolate mofetil—psoriasis	2.98e-05	0.000218	CcSEcCtD
Efavirenz—Urticaria—Triamcinolone—psoriasis	2.97e-05	0.000217	CcSEcCtD
Efavirenz—Dysgeusia—Methotrexate—psoriasis	2.96e-05	0.000216	CcSEcCtD
Efavirenz—Body temperature increased—Triamcinolone—psoriasis	2.95e-05	0.000216	CcSEcCtD
Efavirenz—Dizziness—Cyclosporine—psoriasis	2.95e-05	0.000216	CcSEcCtD
Efavirenz—Decreased appetite—Betamethasone—psoriasis	2.95e-05	0.000215	CcSEcCtD
Efavirenz—Decreased appetite—Dexamethasone—psoriasis	2.95e-05	0.000215	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Betamethasone—psoriasis	2.93e-05	0.000214	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Dexamethasone—psoriasis	2.93e-05	0.000214	CcSEcCtD
Efavirenz—Back pain—Methotrexate—psoriasis	2.92e-05	0.000214	CcSEcCtD
Efavirenz—Hypersensitivity—Hydrocortisone—psoriasis	2.92e-05	0.000213	CcSEcCtD
Efavirenz—Fatigue—Betamethasone—psoriasis	2.92e-05	0.000213	CcSEcCtD
Efavirenz—Fatigue—Dexamethasone—psoriasis	2.92e-05	0.000213	CcSEcCtD
Efavirenz—Shock—Prednisone—psoriasis	2.9e-05	0.000212	CcSEcCtD
Efavirenz—Pain—Dexamethasone—psoriasis	2.9e-05	0.000212	CcSEcCtD
Efavirenz—Pain—Betamethasone—psoriasis	2.9e-05	0.000212	CcSEcCtD
Efavirenz—Nervous system disorder—Prednisone—psoriasis	2.9e-05	0.000211	CcSEcCtD
Efavirenz—Tachycardia—Prednisone—psoriasis	2.88e-05	0.00021	CcSEcCtD
Efavirenz—Dizziness—Mycophenolate mofetil—psoriasis	2.88e-05	0.00021	CcSEcCtD
Efavirenz—Skin disorder—Prednisone—psoriasis	2.87e-05	0.000209	CcSEcCtD
Efavirenz—Hyperhidrosis—Prednisone—psoriasis	2.85e-05	0.000208	CcSEcCtD
Efavirenz—Vision blurred—Methotrexate—psoriasis	2.85e-05	0.000208	CcSEcCtD
Efavirenz—Asthenia—Hydrocortisone—psoriasis	2.85e-05	0.000208	CcSEcCtD
Efavirenz—Vomiting—Cyclosporine—psoriasis	2.84e-05	0.000207	CcSEcCtD
Efavirenz—Rash—Cyclosporine—psoriasis	2.81e-05	0.000206	CcSEcCtD
Efavirenz—Anorexia—Prednisone—psoriasis	2.81e-05	0.000205	CcSEcCtD
Efavirenz—Dermatitis—Cyclosporine—psoriasis	2.81e-05	0.000205	CcSEcCtD
Efavirenz—Pruritus—Hydrocortisone—psoriasis	2.81e-05	0.000205	CcSEcCtD
Efavirenz—Ill-defined disorder—Methotrexate—psoriasis	2.8e-05	0.000205	CcSEcCtD
Efavirenz—Headache—Cyclosporine—psoriasis	2.8e-05	0.000204	CcSEcCtD
Efavirenz—Anaemia—Methotrexate—psoriasis	2.79e-05	0.000204	CcSEcCtD
Efavirenz—Feeling abnormal—Dexamethasone—psoriasis	2.79e-05	0.000204	CcSEcCtD
Efavirenz—Feeling abnormal—Betamethasone—psoriasis	2.79e-05	0.000204	CcSEcCtD
Efavirenz—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	2.79e-05	0.00311	CbGpPWpGaD
Efavirenz—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.78e-05	0.00309	CbGpPWpGaD
Efavirenz—Gastrointestinal pain—Dexamethasone—psoriasis	2.77e-05	0.000202	CcSEcCtD
Efavirenz—Gastrointestinal pain—Betamethasone—psoriasis	2.77e-05	0.000202	CcSEcCtD
Efavirenz—Vomiting—Mycophenolate mofetil—psoriasis	2.77e-05	0.000202	CcSEcCtD
Efavirenz—Hypersensitivity—Triamcinolone—psoriasis	2.75e-05	0.000201	CcSEcCtD
Efavirenz—Rash—Mycophenolate mofetil—psoriasis	2.75e-05	0.000201	CcSEcCtD
Efavirenz—Dermatitis—Mycophenolate mofetil—psoriasis	2.74e-05	0.0002	CcSEcCtD
Efavirenz—Headache—Mycophenolate mofetil—psoriasis	2.73e-05	0.000199	CcSEcCtD
Efavirenz—Malaise—Methotrexate—psoriasis	2.73e-05	0.000199	CcSEcCtD
Efavirenz—Vertigo—Methotrexate—psoriasis	2.72e-05	0.000198	CcSEcCtD
Efavirenz—Diarrhoea—Hydrocortisone—psoriasis	2.71e-05	0.000198	CcSEcCtD
Efavirenz—Urticaria—Betamethasone—psoriasis	2.69e-05	0.000197	CcSEcCtD
Efavirenz—Urticaria—Dexamethasone—psoriasis	2.69e-05	0.000197	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Prednisone—psoriasis	2.69e-05	0.000196	CcSEcCtD
Efavirenz—Dizziness—Prednisolone—psoriasis	2.69e-05	0.000196	CcSEcCtD
Efavirenz—Asthenia—Triamcinolone—psoriasis	2.68e-05	0.000196	CcSEcCtD
Efavirenz—Body temperature increased—Dexamethasone—psoriasis	2.68e-05	0.000196	CcSEcCtD
Efavirenz—Abdominal pain—Betamethasone—psoriasis	2.68e-05	0.000196	CcSEcCtD
Efavirenz—Body temperature increased—Betamethasone—psoriasis	2.68e-05	0.000196	CcSEcCtD
Efavirenz—Abdominal pain—Dexamethasone—psoriasis	2.68e-05	0.000196	CcSEcCtD
Efavirenz—Insomnia—Prednisone—psoriasis	2.67e-05	0.000195	CcSEcCtD
Efavirenz—Nausea—Cyclosporine—psoriasis	2.65e-05	0.000194	CcSEcCtD
Efavirenz—Paraesthesia—Prednisone—psoriasis	2.65e-05	0.000194	CcSEcCtD
Efavirenz—Pruritus—Triamcinolone—psoriasis	2.64e-05	0.000193	CcSEcCtD
Efavirenz—Cough—Methotrexate—psoriasis	2.64e-05	0.000193	CcSEcCtD
Efavirenz—Dizziness—Hydrocortisone—psoriasis	2.62e-05	0.000192	CcSEcCtD
Efavirenz—Convulsion—Methotrexate—psoriasis	2.62e-05	0.000191	CcSEcCtD
Efavirenz—Dyspepsia—Prednisone—psoriasis	2.6e-05	0.00019	CcSEcCtD
Efavirenz—Nausea—Mycophenolate mofetil—psoriasis	2.59e-05	0.000189	CcSEcCtD
Efavirenz—Chest pain—Methotrexate—psoriasis	2.57e-05	0.000188	CcSEcCtD
Efavirenz—Myalgia—Methotrexate—psoriasis	2.57e-05	0.000188	CcSEcCtD
Efavirenz—Arthralgia—Methotrexate—psoriasis	2.57e-05	0.000188	CcSEcCtD
Efavirenz—Decreased appetite—Prednisone—psoriasis	2.57e-05	0.000187	CcSEcCtD
Efavirenz—Rash—Prednisolone—psoriasis	2.56e-05	0.000187	CcSEcCtD
Efavirenz—Dermatitis—Prednisolone—psoriasis	2.56e-05	0.000187	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.56e-05	0.000187	CcSEcCtD
Efavirenz—Fatigue—Prednisone—psoriasis	2.55e-05	0.000186	CcSEcCtD
Efavirenz—Headache—Prednisolone—psoriasis	2.55e-05	0.000186	CcSEcCtD
Efavirenz—Discomfort—Methotrexate—psoriasis	2.54e-05	0.000186	CcSEcCtD
Efavirenz—Constipation—Prednisone—psoriasis	2.52e-05	0.000184	CcSEcCtD
Efavirenz—Vomiting—Hydrocortisone—psoriasis	2.52e-05	0.000184	CcSEcCtD
Efavirenz—Rash—Hydrocortisone—psoriasis	2.5e-05	0.000183	CcSEcCtD
Efavirenz—Dermatitis—Hydrocortisone—psoriasis	2.5e-05	0.000183	CcSEcCtD
Efavirenz—Confusional state—Methotrexate—psoriasis	2.49e-05	0.000182	CcSEcCtD
Efavirenz—Headache—Hydrocortisone—psoriasis	2.49e-05	0.000182	CcSEcCtD
Efavirenz—Dizziness—Triamcinolone—psoriasis	2.47e-05	0.00018	CcSEcCtD
Efavirenz—Feeling abnormal—Prednisone—psoriasis	2.43e-05	0.000178	CcSEcCtD
Efavirenz—Asthenia—Dexamethasone—psoriasis	2.43e-05	0.000178	CcSEcCtD
Efavirenz—Asthenia—Betamethasone—psoriasis	2.43e-05	0.000178	CcSEcCtD
Efavirenz—Nervous system disorder—Methotrexate—psoriasis	2.42e-05	0.000177	CcSEcCtD
Efavirenz—Thrombocytopenia—Methotrexate—psoriasis	2.42e-05	0.000176	CcSEcCtD
Efavirenz—Gastrointestinal pain—Prednisone—psoriasis	2.41e-05	0.000176	CcSEcCtD
Efavirenz—Nausea—Prednisolone—psoriasis	2.41e-05	0.000176	CcSEcCtD
Efavirenz—Pruritus—Dexamethasone—psoriasis	2.4e-05	0.000175	CcSEcCtD
Efavirenz—Pruritus—Betamethasone—psoriasis	2.4e-05	0.000175	CcSEcCtD
Efavirenz—Skin disorder—Methotrexate—psoriasis	2.4e-05	0.000175	CcSEcCtD
Efavirenz—Hyperhidrosis—Methotrexate—psoriasis	2.39e-05	0.000174	CcSEcCtD
Efavirenz—Vomiting—Triamcinolone—psoriasis	2.38e-05	0.000173	CcSEcCtD
Efavirenz—Nausea—Hydrocortisone—psoriasis	2.36e-05	0.000172	CcSEcCtD
Efavirenz—Rash—Triamcinolone—psoriasis	2.36e-05	0.000172	CcSEcCtD
Efavirenz—Dermatitis—Triamcinolone—psoriasis	2.35e-05	0.000172	CcSEcCtD
Efavirenz—Anorexia—Methotrexate—psoriasis	2.35e-05	0.000172	CcSEcCtD
Efavirenz—Urticaria—Prednisone—psoriasis	2.35e-05	0.000171	CcSEcCtD
Efavirenz—Headache—Triamcinolone—psoriasis	2.34e-05	0.000171	CcSEcCtD
Efavirenz—Body temperature increased—Prednisone—psoriasis	2.33e-05	0.00017	CcSEcCtD
Efavirenz—Abdominal pain—Prednisone—psoriasis	2.33e-05	0.00017	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.32e-05	0.00258	CbGpPWpGaD
Efavirenz—Diarrhoea—Betamethasone—psoriasis	2.32e-05	0.000169	CcSEcCtD
Efavirenz—Diarrhoea—Dexamethasone—psoriasis	2.32e-05	0.000169	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Methotrexate—psoriasis	2.25e-05	0.000164	CcSEcCtD
Efavirenz—Dizziness—Dexamethasone—psoriasis	2.24e-05	0.000164	CcSEcCtD
Efavirenz—Dizziness—Betamethasone—psoriasis	2.24e-05	0.000164	CcSEcCtD
Efavirenz—Insomnia—Methotrexate—psoriasis	2.23e-05	0.000163	CcSEcCtD
Efavirenz—Nausea—Triamcinolone—psoriasis	2.22e-05	0.000162	CcSEcCtD
Efavirenz—Paraesthesia—Methotrexate—psoriasis	2.22e-05	0.000162	CcSEcCtD
Efavirenz—Dyspnoea—Methotrexate—psoriasis	2.2e-05	0.000161	CcSEcCtD
Efavirenz—Somnolence—Methotrexate—psoriasis	2.19e-05	0.00016	CcSEcCtD
Efavirenz—Hypersensitivity—Prednisone—psoriasis	2.18e-05	0.000159	CcSEcCtD
Efavirenz—Dyspepsia—Methotrexate—psoriasis	2.17e-05	0.000159	CcSEcCtD
Efavirenz—Vomiting—Dexamethasone—psoriasis	2.16e-05	0.000157	CcSEcCtD
Efavirenz—Vomiting—Betamethasone—psoriasis	2.16e-05	0.000157	CcSEcCtD
Efavirenz—Decreased appetite—Methotrexate—psoriasis	2.14e-05	0.000157	CcSEcCtD
Efavirenz—Rash—Dexamethasone—psoriasis	2.14e-05	0.000156	CcSEcCtD
Efavirenz—Rash—Betamethasone—psoriasis	2.14e-05	0.000156	CcSEcCtD
Efavirenz—Dermatitis—Dexamethasone—psoriasis	2.14e-05	0.000156	CcSEcCtD
Efavirenz—Dermatitis—Betamethasone—psoriasis	2.14e-05	0.000156	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Methotrexate—psoriasis	2.13e-05	0.000156	CcSEcCtD
Efavirenz—Fatigue—Methotrexate—psoriasis	2.13e-05	0.000155	CcSEcCtD
Efavirenz—Headache—Dexamethasone—psoriasis	2.12e-05	0.000155	CcSEcCtD
Efavirenz—Headache—Betamethasone—psoriasis	2.12e-05	0.000155	CcSEcCtD
Efavirenz—Asthenia—Prednisone—psoriasis	2.12e-05	0.000155	CcSEcCtD
Efavirenz—Pain—Methotrexate—psoriasis	2.11e-05	0.000154	CcSEcCtD
Efavirenz—Pruritus—Prednisone—psoriasis	2.09e-05	0.000153	CcSEcCtD
Efavirenz—Feeling abnormal—Methotrexate—psoriasis	2.03e-05	0.000148	CcSEcCtD
Efavirenz—Diarrhoea—Prednisone—psoriasis	2.02e-05	0.000147	CcSEcCtD
Efavirenz—Gastrointestinal pain—Methotrexate—psoriasis	2.02e-05	0.000147	CcSEcCtD
Efavirenz—Nausea—Dexamethasone—psoriasis	2.01e-05	0.000147	CcSEcCtD
Efavirenz—Nausea—Betamethasone—psoriasis	2.01e-05	0.000147	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.01e-05	0.00223	CbGpPWpGaD
Efavirenz—Urticaria—Methotrexate—psoriasis	1.96e-05	0.000143	CcSEcCtD
Efavirenz—Dizziness—Prednisone—psoriasis	1.95e-05	0.000143	CcSEcCtD
Efavirenz—Abdominal pain—Methotrexate—psoriasis	1.95e-05	0.000142	CcSEcCtD
Efavirenz—Body temperature increased—Methotrexate—psoriasis	1.95e-05	0.000142	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	1.93e-05	0.00215	CbGpPWpGaD
Efavirenz—Vomiting—Prednisone—psoriasis	1.88e-05	0.000137	CcSEcCtD
Efavirenz—Rash—Prednisone—psoriasis	1.86e-05	0.000136	CcSEcCtD
Efavirenz—Dermatitis—Prednisone—psoriasis	1.86e-05	0.000136	CcSEcCtD
Efavirenz—Headache—Prednisone—psoriasis	1.85e-05	0.000135	CcSEcCtD
Efavirenz—Hypersensitivity—Methotrexate—psoriasis	1.82e-05	0.000133	CcSEcCtD
Efavirenz—Asthenia—Methotrexate—psoriasis	1.77e-05	0.000129	CcSEcCtD
Efavirenz—Nausea—Prednisone—psoriasis	1.75e-05	0.000128	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.75e-05	0.00195	CbGpPWpGaD
Efavirenz—Pruritus—Methotrexate—psoriasis	1.75e-05	0.000127	CcSEcCtD
Efavirenz—Diarrhoea—Methotrexate—psoriasis	1.69e-05	0.000123	CcSEcCtD
Efavirenz—CYP2B6—Metabolism—NDUFA5—psoriasis	1.65e-05	0.00184	CbGpPWpGaD
Efavirenz—Dizziness—Methotrexate—psoriasis	1.63e-05	0.000119	CcSEcCtD
Efavirenz—Vomiting—Methotrexate—psoriasis	1.57e-05	0.000115	CcSEcCtD
Efavirenz—Rash—Methotrexate—psoriasis	1.56e-05	0.000114	CcSEcCtD
Efavirenz—Dermatitis—Methotrexate—psoriasis	1.55e-05	0.000113	CcSEcCtD
Efavirenz—Headache—Methotrexate—psoriasis	1.55e-05	0.000113	CcSEcCtD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.5e-05	0.00167	CbGpPWpGaD
Efavirenz—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.5e-05	0.00167	CbGpPWpGaD
Efavirenz—Nausea—Methotrexate—psoriasis	1.47e-05	0.000107	CcSEcCtD
Efavirenz—CYP2B6—Metabolism—CYP2S1—psoriasis	1.41e-05	0.00156	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—NDUFA5—psoriasis	1.25e-05	0.00139	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.17e-05	0.0013	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—NDUFA5—psoriasis	1.15e-05	0.00128	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—NDUFA5—psoriasis	1.14e-05	0.00127	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CYP2S1—psoriasis	1.06e-05	0.00118	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.06e-05	0.00118	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CYP2S1—psoriasis	9.77e-06	0.00109	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—NDUFA5—psoriasis	9.74e-06	0.00108	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CYP2S1—psoriasis	9.69e-06	0.00108	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.08e-06	0.00101	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CYP2S1—psoriasis	8.28e-06	0.000921	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—NDUFA5—psoriasis	7.52e-06	0.000836	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CARM1—psoriasis	6.87e-06	0.000764	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CYP2S1—psoriasis	6.39e-06	0.000711	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.57e-06	0.00062	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CARM1—psoriasis	5.19e-06	0.000578	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.08e-06	0.000565	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.85e-06	0.00054	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CARM1—psoriasis	4.77e-06	0.000531	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CARM1—psoriasis	4.73e-06	0.000527	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.42e-06	0.000492	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.34e-06	0.000483	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—CAT—psoriasis	4.22e-06	0.00047	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CARM1—psoriasis	4.04e-06	0.00045	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.78e-06	0.000421	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—APOE—psoriasis	3.28e-06	0.000365	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—CAT—psoriasis	3.19e-06	0.000355	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CARM1—psoriasis	3.12e-06	0.000347	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—CAT—psoriasis	2.94e-06	0.000327	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—CAT—psoriasis	2.91e-06	0.000324	CbGpPWpGaD
Efavirenz—CYP2B6—Metabolism—PPARG—psoriasis	2.86e-06	0.000318	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—CAT—psoriasis	2.49e-06	0.000277	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—APOE—psoriasis	2.48e-06	0.000276	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—APOE—psoriasis	2.28e-06	0.000254	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—APOE—psoriasis	2.26e-06	0.000252	CbGpPWpGaD
Efavirenz—CYP2C19—Metabolism—PPARG—psoriasis	2.16e-06	0.00024	CbGpPWpGaD
Efavirenz—CYP2D6—Metabolism—PPARG—psoriasis	1.99e-06	0.000221	CbGpPWpGaD
Efavirenz—CYP2C9—Metabolism—PPARG—psoriasis	1.97e-06	0.000219	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—APOE—psoriasis	1.93e-06	0.000215	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—CAT—psoriasis	1.92e-06	0.000214	CbGpPWpGaD
Efavirenz—CYP1A2—Metabolism—PPARG—psoriasis	1.68e-06	0.000187	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—APOE—psoriasis	1.49e-06	0.000166	CbGpPWpGaD
Efavirenz—CYP3A4—Metabolism—PPARG—psoriasis	1.3e-06	0.000145	CbGpPWpGaD
